Federal Register of Legislation - Australian Government

Primary content

SR 1998 No. 303 Regulations as made
Principal Regulations. These regulations repeal the Health Insurance (1997-98 Pathology Services Table) Regulations.
Tabling HistoryDate
Tabled HR10-Nov-1998
Tabled Senate10-Nov-1998
Gazetted 30 Oct 1998
Date of repeal 01 Nov 1999
Repealed by Health Insurance (1999-2000 Pathology Services Table) Regulations 1999
Table of contents.

Health Insurance (1998–99 Pathology Services Table) Regulations 1998

Statutory Rules 1998    No. 303

I, WILLIAM PATRICK DEANE, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following regulations under the Health Insurance Act 1973.

Dated 27 October 1998.

                                                                          WILLIAM DEANE
                                                                            Governor-General

By His Excellency’s Command,

Michael wooldridge


Health Insurance (1998–99 Pathology Services Table) Regulations 1998

Statutory Rules 1998    No. 3031

made under the

Health Insurance Act 1973

 

 

 

Contents

Page

                        1     Name of regulations                                                       

                        2     Commencement                                                             

                        3     Pathology Services Table                                               

                        4     Repeals                                                                         

Schedule 1       Table of pathology services                                  

Part 1               Rules of interpretation                                                    

Part 2               Services and fees

Part 3               Abbreviations                                                              

Part 4               Complexity levels for histopathology items                 

 


Do not delete : Part placeholder

Do not delete : Division placeholder

1       Name of regulations

                These regulations are the Health Insurance (1998–99 Pathology Services Table) Regulations 1998.

2       Commencement

                These regulations commence on 1 November 1998.

3       Pathology Services Table

                The table of pathology services in Schedule 1 is prescribed for subsection 4A (1) of the Health Insurance Act 1973.

4       Repeals

                The following statutory rules are repealed:

·           Health Insurance (1997–98 Pathology Services Table) Regulations 1997 No. 299

·           Health Insurance (1997–98 Pathology Services Table) Regulations (Amendment) 1998 No. 203.


Schedule 1        Table of pathology services

(regulation 3)

Part 1          Rules of interpretation

1       Interpretation of table

         (1)   In this table:

patient episode means:

                (a)    a pathology service or pathology services (other than a pathology service to which paragraph (b) refers) provided for a single patient whose need for the service or services was determined under section 16A of the Act:

                          (i)    on the same day; or

                         (ii)    if more than 1 test is performed on the 1 specimen within 14 days — on the same or different days;

                        whether the services:

                        (iii)    are requested by 1 or more practitioners; or

                        (iv)    are described in a single item or in more than 1 item; or

                         (v)    are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or

                        (vi)    are rendered on the same or different days; or

               (b)    a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relates to the service.

recognised pathologist means a medical practitioner recognised as a specialist in pathology by a determination under section 3D or subsection 61 (3) of the Act.

serial examinations means a series of examinations requested on 1 occasion whether or not:

                (a)    the materials are received on different days by the approved pathology practitioner; or

               (b)    the examinations or cultures were requested on 1 or more request forms by the treating practitioner.

the Act means the Health Insurance Act 1973.

         (2)   In these rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies.

         (3)   A reference in this table by number to an item that is not included in this table is a reference to the item that has that number in the general medical services table or the diagnostic imaging services table, as the case requires.

         (4)   A reference to a Group in the table includes every item in the Group.

2       Precedence of items

         (1)   If a service is described:

                (a)    in an item in general terms; and

               (b)    in another item in specific terms;

                 only the item that describes the service in specific terms applies to the service.

         (2)   Subject to subrule (3), if:

                (a)    subrule (1) does not apply; and

               (b)    a service is described in 2 or more items;

                        only the item that provides the lower or lowest fee for the service applies to the service.

         (3)   If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.

3       Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request

         (1)   In subrule (2), service includes assay, estimation and test.

         (2)   Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:

                (a)    the services are listed in the same item; and

               (b)    the patient’s need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than one day.

4       Services to which rule 3 does not apply

         (1)   Rule 3 does not apply to a pathology service described in item 66500 or 66584, if:

                (a)    the service is rendered in relation to a single specimen taken on each of not more than 4 occasions in a period of 24 hours; and

               (b)    the service is rendered to a patient in a hospital unit where:

                          (i)    the presence of 1 nurse is required for each group of not more than 4 patients; and

                         (ii)    the condition of the patients is continuously observed in relevant respects; and

                (c)    in order to render the service, an approved pathology practitioner who is a recognised pathologist has to arrange for a member of the laboratory staff of the approved pathology authority concerned to undertake duties in respect of the service that are in addition to the usual duties of the staff member; and

               (d)    the account for the service is endorsed “Rule 3 Exemption”.

         (2)   Rule 3 does not apply to any of the following pathology services:

                (a)    estimation of prothrombin time (INR) in respect of a patient undergoing anticoagulant therapy;

               (b)    quantitative estimation of lithium in respect of a patient undergoing lithium therapy;

                (c)    a service described in item 65063 or 65069 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;

               (d)    a service described in item 65063 or 65069 in relation to clozaril, ticlopidine hydrochloride, methotrexate, gold, sulfasalazine or penicillamine therapy of a patient;

                (e)    a service described in item 66500 in relation to methotrexate therapy of a patient;

                (f)    quantitative estimation of urea, creatinine and electrolytes in relation to:

                          (i)    cis-platinum therapy of a patient; or

                         (ii)    chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital;

               (g)    quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues;

                if:

               (h)    under a request for a service, other than a request for a service described in paragraph (a), no more than 6 tests are requested; and

                (i)    the tests are performed within 6 months of the request; and

                (j)    the account for the service is endorsed “Rule 3 Exemption”.

5       Item taken to refer only to the first service of a particular kind

         (1)   For an item in Group P1 (Haematology):

                (a)    if pathology services of a kind referred to in item 65090 or 65093 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and

               (b)    if:

                          (i)    tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out in relation to a patient episode; and

                         (ii)    specimen material from the patient episode is stored; and

                        (iii)    in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out on the stored material;

                        the later tests and the earlier tests are taken to be part of one patient episode.

         (2)   Benefits for items 65102 and 65108 are payable only if the first 6 units were transfused into a patient within 24 hours.

         (3)   For items 65099 and 65102:

compatibility tests by crossmatch means that, in addition to all the tests described in (a) and (b) of the item, donor red cells from each unit must have been tested directly against the serum of the patient by 1 or more accepted crossmatching techniques.

6       Certain items not to apply to a service referred by one pathology practitioner to another

         (1)   In this rule:

designated pathology service means a pathology service in respect of tests relating to a single patient episode that are:

                (a)    tests of the kind described in item 66611; or

               (b)    tests of the kind described in item 66695; or

                (c)    tests of the kind described in item 66722; or

               (d)    tests of the kind described in item 69384.

         (2)   This rule applies in respect of a designated pathology service where:

                (a)    an approved pathology practitioner (practitioner A) in an approved pathology authority:

                          (i)    has been requested to render the designated pathology service; and

                         (ii)    is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more (but not all) of the tests included in the service; and

                        (iii)    requests an approved pathology practitioner (practitioner B) in another approved pathology authority to render the test or tests that practitioner A is unable to render; and

                        (iv)    renders each test included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and

               (b)    the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 66617, 66710, 66734 or 69399.

         (3)   If this rule applies in respect of a designated pathology service:

                (a)    item 66611, 66614, 66695, 66698, 66701, 66704, 66707, 66722, 66725, 66728, 66731, 69384, 69387, 69390, 69393 or 69396 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and

               (b)    where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) — subject to subrule (4), the amount specified in item 66620, 66713, 66737 or 69402 (as the case requires) is payable for each test that the service comprises.

         (4)   For paragraph (3) (b), the maximum number of tests to which item 66620, 66713, 66737 or 69402 applies is:

                (a)    for item 66620:

                                                       3 – X; or

               (b)    for item 66713, 66737 or 69402:

                                                      6 – X;

where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.

         (5)   Items in Group P10 (Patient episode initiation) do not apply to the second-mentioned approved pathology practitioner in subrule (2).

7       Items not to be split

                Except as stated in rule 6, the amount specified in an item is payable only to one approved pathology practitioner in respect of a single patient episode.

8       Certain tests on stored material to be treated as part of the same patient episode

                For items in Group P2 (Chemical):

                (a)    if a pathology service that involves the measurement of a substance in urine requires calculation of a substance/creatinine ratio, the service is taken to include the measurement of creatinine necessary for the calculation; and

               (b)    if:

                          (i)    tests are carried out in relation to a patient episode; and

                         (ii)    specimen material from the patient episode is stored; and

                        (iii)    in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

                        the later tests and the earlier tests are taken to be part of one patient episode.

9       Item 66536

                The amount specified in item 66536 is not payable in respect of a pathology service described in the item unless at least one of the following paragraphs applies:

                (a)    if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a serum cholesterol level >5.5 mmol/L — the determination is performed on the sample that the serum cholesterol level determination for the patient was performed;

               (b)    if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a fasting serum triglyceride level >2.0 mmol/L — the determination is performed on the sample that the serum triglyceride level determination for the patient was performed;

                (c)    the pathologist who renders the service has a written statement from the medical practitioner who requested the service that the patient is on a lipid lowering drug.

10     Thyroid function testing

         (1)   For item 66719:

abnormal level of TSH means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.

         (2)   Except where paragraph (a) of item 66719 is satisfied, the amount specified in the item is not payable in respect of a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).

         (3)   The written statement from the medical practitioner must indicate:

                (a)    that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66719; or

               (b)    that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or

                (c)    that the patient is on drugs that interfere with thyroid hormone metabolism or function.

11     Meaning of serial examinations or cultures

                For an item in Group P3 (Microbiology):

                (a)    serial examinations or cultures means a series of examinations or cultures requested on 1 occasion whether or not:

                          (i)    the materials are received on different days by the approved pathology practitioner; or

                         (ii)    the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and

               (b)    if:

                          (i)    tests are carried out in relation to a patient episode; and

                         (ii)    specimen material from the patient episode is stored; and

                        (iii)    in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

                        the later tests and the earlier tests are taken to be part of one patient episode.

12     Investigation for hepatitis and syphilis serology

         (1)   A medicare benefit is not payable in respect of more than one of items 69414, 69417, 69420, 69423, 69426, 69429, 69432, 69435, 69438, 69447, 69450, 69453, 69456, 69459, 69462, 69465 and 69468 in a patient episode.

         (2)   For items 69459 and 69468, currently elevated transaminase level means a level of alanine aminotransferase or aspartate aminotransferase above the normal reference range in respect of the particular method of assay used to determine the level, as disclosed by a test carried out on a sample taken for the investigation or on a sample taken within the previous 7 days.

13     Tests in Group P4 (Immunology) relating to antibodies

                For items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:

                (a)    tests are carried out in relation to a patient episode; and

               (b)    specimen material from the patient episode is stored; and

                (c)    in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

                 the later tests and the earlier tests are taken to be part of one patient episode.

14     Tests on biopsy material — Group P5 (Tissue pathology) and Group P6 (Cytology)

         (1)   For items in Group P5 (Tissue pathology):

                (a)    biopsy material means all tissue (other than a bone marrow biopsy) received by an approved pathology practitioner from an operation, or a group of operations, performed on a patient at the same time; and

               (b)    if:

                          (i)    a pathology service that comprises the examination of biopsy material is rendered under any of those items; and

                         (ii)    a further pathology service mentioned in any of those items is also rendered using that biopsy material;

                        those pathology services are taken to be 1 pathology service; and

                (c)    cytology means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film and a bone marrow aspirate; and

               (d)    separately identified specimen means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken.

         (2)   For Groups P5 and P6 of the pathology services table, services in Group P6 include any services described in
Group P5 on the material submitted for a test in Group P6.

         (3)   For subrule (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

         (4)   If more than 1 of the services mentioned in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 are performed in a single patient episode, a medicare benefit is payable only for the item performed that has the highest schedule fee.

         (5)   If more than 1 histopathological examinations are performed on separate specimens, of different complexity levels, from a single patient episode, a medicare benefit is payable only for the examination that has the highest schedule fee.

         (6)   In items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 a reference to a complexity level is a reference to the level given to a specimen type mentioned in Part 4 of this table.

15     Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances

         (1)   For this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):

institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

                (a)    disadvantaged children; or

               (b)    juvenile offenders; or

                (c)    aged persons; or

               (d)    chronically ill psychiatric patients; or

                (e)    homeless persons; or

                (f)    unemployed persons; or

               (g)    persons suffering from alcoholism; or

               (h)    persons addicted to drugs; or

                (i)    physically or mentally handicapped persons;

                but does not include:

                (j)    a hospital; or

               (k)    a nursing home; or

                (l)    accommodation for aged persons that is attached to a nursing home or situated within a nursing home complex.

licensed collection centre has the same meaning as in Part IIA of the Act.

prescribed laboratory means a laboratory operated by:

                (a)    the Commonwealth; or

               (b)    a State or internal Territory; or

                (c)    an authority of a State or internal Territory; or

               (d)    an Australian tertiary education institution.

specimen collection centre has the same meaning as in Part IIA of the Act.

treating practitioner has the same meaning as in paragraph 16A (1) (a) of the Act.

         (2)   If a service described in an item in Group P10 or P11 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:

                (a)    the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or

               (b)    the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request is made; or

                (c)    the pathology equipment of a recognised hospital, or a prescribed laboratory, is used rendering the service; or

               (d)    a member of the staff of a recognised hospital, or a prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory.

         (3)   An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A (7) of the Act applies.

         (4)   An item in Group P10 or P11 does not apply to a pathology service unless at least one item in Groups P1 to P8 also applies to the service.

         (5)   Subject to subrule (7), if one item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode.

         (6)   An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.

         (7)   If, in respect of the same patient episode:

                (a)    services referred to in 1 or more items in Group P5 and 1 or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; and

               (b)    services referred to in 1 or more items in Group P6 and 1 or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by another approved pathology practitioner in another approved pathology authority;

                        the fee specified in the applicable item in Group P10 is payable to both approved pathology practitioners.

         (8)   If more than one specimen is collected from a person on the same day for the provision of pathology services:

                (a)    in accordance with more than one request; and

               (b)    in or by a single approved pathology authority;

                        only a single amount specified in the applicable item in Group P10 is payable for the services.

         (9)   The amount specified in item 73921 is payable only once in respect of a single patient episode.

16     Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

                If item 73921 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology practitioner who claimed item 73921 in respect of the patient episode.

17     Circumstances in which an item in Group P11 (Specimen referred) does not apply

         (1)   An item in Group P11 does not apply to a referral if:

                (a)    a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and

               (b)    the approved pathology authority to which the referral is made is related to the referring approved pathology authority.

         (2)   An approved pathology authority is related to another approved pathology authority for subrule (1) if:

                (a)    both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or

               (b)    either of the approved pathology authorities is employed (including employed under contract) by the other; or

                (c)    both approved pathology authorities are corporations and are related corporations within the meaning of the Corporations Law; or

               (d)    the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities).

         (3)   An item in Group P11 does not apply to a referral if the following common tests are referred either singly or in combination (except if the following items are referred in combination with other items not similarly specified): 65060, 65063, 65069, 65120, 66500, 66503, 66506, 66509, 66512, 66515, 66521, 66524, 66527, 66530, 66533, 66536, 66596, 69300, 69303, 69333 or 73527.

18     Abbreviations

         (1)   The abbreviations in Part 3 of this table may be used to identify particular pathology services or groups of pathology services.

         (2)   The names of services or drugs not listed in Part 3 of this table must be written in full.

19     Certain pathology services to be treated as 1 service

         (1)   In this rule:

general practitioner means a medical practitioner who:

                (a)    is not a consultant physician in any specialty; and

               (b)    is not a specialist in any specialty.

set of pathology services means a group of pathology services:

                (a)    that consists of services that are described in at least 4 different items; and

               (b)    all of which are requested in a single patient episode; and

                (c)    each of which relates to a patient who is not an admitted patient of a hospital; and

               (d)    none of which is referred to:

                          (i)    in item 66620, 66713, 66737, or 69402; or

                         (ii)    in an item in Group P10 (Patient episode initiation) or Group P11 (Specimen referred).

         (2)   If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.

         (3)   If the fee specified in one item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:

                (a)    the pathology service described in the first-mentioned item is to be treated as one pathology service; and

               (b)    either:

                          (i)    the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as one pathology service; or

                         (ii)    if 2 or more items that describe any of those services specify the second-highest fee — the pathology service described in the item that specifies the second-highest fee, and has the lowest item number, is to be treated as one pathology service; and

                (c)    the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

         (4)   If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:

                (a)    the pathology service in the set that is described in the item that specifies the highest fee, and has the lowest item number, is to be treated as one pathology service; and

               (b)    the pathology service in the set that is described in the item that specifies the highest fee, and has the second‑lowest item number, is to be treated as one pathology service; and

                (c)    the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

         (5)   If pathology services are to be treated as one pathology service under paragraph (3) (c) or (4) (c), the fee for the one pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the one pathology service.

20     HIV viral RNA load testing

                For items 69378 and 69381, no more than a maximum of 6 episodes for either item 69378 or item 69381, or any combination for both items, can be claimed in a 12 month period.

21     Hepatitis C viral RNA testing

                For item 69444:

Hepatitis C sero-positive, for a patient, means 2 different assays of Hepatitis C antibodies are positive.

serological status is uncertain, for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.

22     Haemochromatosis testing

                For item 66794:

elevated serum ferritin, for a patient, means a level of ferritin above the normal reference range in respect of the particular method of assay used to determine the level.

 

Part 2          Services and fees

 

Category 6            Pathology services

 

 

Item

Pathology service

Fee   ($)

 

Group P1 — Haematology

65060

Haemoglobin, erythrocyte sedimentation rate, blood viscosity — 1 or more tests

7.70

 

 

 

65063

Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and instrument generated differential count — including any services in item 65060 or 65072 — 2 or more instrument generated results from a single sample

17.20

 

 

 

65066

Examination of:

(a)  a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or

(b)  a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha‑naphthyl acetate esterase or chloroacetate esterase; or

(c)  a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or

(d)  a urinary sediment for haemosiderin;

including a service described in item 65072

10.25

 

 

 

65069

Full blood examination consisting of:

(a)  a morphological assessment of a blood film; and

(b)  item 65063; and

(c)  (if performed) any test in item 65060 or 65072

17.20

 

 

 

65072

Examination for reticulocytes including a reticulocyte count by any method — 1 or more tests in any episode

10.00

 

 

 

65075

Haemolysis or metabolic enzymes — assessment by:

(a)  erythrocyte autohaemolysis test; or

(b)  erythrocyte osmotic fragility test; or

(c)  sugar water test; or

(d)  G‑6‑P D (qualitative or quantitative) test; or

(e)  pyruvate kinase (qualitative or quantitative) test; or

(f)   acid haemolysis test; or

(g)  quantitation of muramidase in serum or urine; or

(h)  Donath Landsteiner antibody test; or

(i)   other erythrocyte metabolic enzyme tests;

1 or more tests

46.60

 

 

 

65078

Tests for the diagnosis of thalassaemia when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 2 of:

(a)  examination for HbH; or

(b)  quantitation of HbA2; or

(c)  quantitation of HbF;

including (if performed) any service described in item 65060 or 65063 or 65069

80.90

 

 

 

65081

Tests for the investigation of haemoglobinopathy (including S, C, D, E), other than thalassaemia, when indicated on the basis of an abnormal full blood examination or by the clinical need for family studies, consisting of haemoglobin electrophoresis or chromatography and at least 1 of:

(a)  heat denaturation test; or

(b)  isopropanol precipitation test; or

(c)  tests for the presence of haemoglobin S; or

(d)  quantitation of any haemoglobin fraction (including S, C, D, E);

including (if performed) any service described in item 65060, 65063, 65069 or 65078

86.70

 

 

 

65084

Bone marrow trephine biopsy — histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed):

(a)  special stains or immunohistochemical techniques (if any); and

(b)  any test described in item 65060, 65063, 65066 or 65069

163.70

 

 

 

65087

Bone marrow — examination of aspirated material (including clot sections where necessary), including (if performed):

(a)  special stains or immunohistochemical techniques (if any); and

(b)  any test described in item 65060, 65063, 65066 or 65069

82.00

 

 

 

65090

Blood grouping (including back‑grouping if performed) — ABO and Rh (D antigen)

10.90

 

 

 

65093

Blood grouping — Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system — 1 or more systems, including item 65090 (if performed)

21.70

 

 

 

65096

Blood grouping (including back‑grouping if performed), and examination of serum for Rh and other blood group antibodies, including:

(a)  identification and quantitation of any antibodies detected; and

(b)  (if performed) any test described in item 65060, 65063 or 65069

40.40

 

 

 

65099

Compatibility tests by crossmatch — all tests performed on any one day for up to 6 units, including:

(a)  all grouping checks of the patient and donor; and

(b)  examination for antibodies, and if necessary identification of any antibodies detected; and

(c)  (if performed) any tests described in item 65060, 65063, 65069, 65090 or 65096

(Item is subject to rule 5)

109.75

 

 

 

65102

Compatibility tests by crossmatch — all tests performed on any one day in excess of 6 units, including:

(a)  all grouping checks of the patient and donor; and

(b)  examination for antibodies, and if necessary identification of any antibodies detected; and

(c)  (if performed) any tests described in item 65060, 65063, 65069, 65090, 65096, 65099 or 65105

(Item is subject to rule 5)

165.00

 

 

 

65105

Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any one day for up to 6 units, including:

(a)  all grouping checks of the patient and donor; and

(b)  examination for antibodies and, if necessary, identification of any antibodies detected; and

(c)  (if performed) any tests described in item 65060, 65063, 65069, 65090 or 65096

(Item is subject to rule 5)

88.00

 

 

 

65108

Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any one day in excess of 6 units, including:

(a)  all grouping checks of the patient and donor; and

(b)  examination for antibodies and, if necessary, identification of any antibodies detected; and

(c)  (if performed) any tests described in item 65060, 65063, 65069, 65090, 65096, 65099 or 65105

(Item is subject to rule 5)

143.00

 

 

 

65111

Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)

22.90

 

 

 

65114

1 or more of the following tests:

(a)  direct Coombs (antiglobulin) test;

(b)  qualitative or quantitative test for cold agglutinins or heterophil antibodies

8.95

 

 

 

65117

1 or more of the following tests:

(a)  qualitative spectroscopic examination of blood for chemically altered haemoglobins;

(b)  detection of methaemalbumin (Schumm’s test)

20.00

 

 

 

65120

Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or 1 of fibrinogen degradation products, fibrin monomer or D‑dimer — 1 test

13.65

 

 

 

65123

2 tests described in item 65120

18.05

 

 

 

65126

3 tests described in item 65120

22.45

 

 

 

65129

4 or more tests described in item 65120

26.85

 

 

 

65132

Quantitation, by 1 or more techniques, of antithrombin III, Protein C, Protein S, heparin cofactor II, plasminogen, euglobulin clot lysis time and test for lupus anticoagulant — 1 to 3 tests

39.40

 

 

 

65138

4 or more tests described in item 65132

92.90

 

 

 

65141

Test for Activated Protein C resistance for a patient with a history of venous thrombosis or pulmonary thromboembolism — where any request for the test by a medical practitioner specifically identifies in writing a history of venous thrombosis or pulmonary thromboembolism

24.00

 

 

 

65144

Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances; or heparin, low molecular weight heparins, heparinoid or other drugs — 1 or more tests

55.80

 

 

 

65147

Quantitation of anti‑Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid — 1 test

37.40

 

 

 

65150

Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay — 1 test

56.10

 

 

 

65153

2 tests described in item 65150

110.20

 

 

 

65156

3 or more tests described in item 65150

161.90

 

 

 

65159

Quantitation of circulating coagulation factor inhibitors by Bethesda assay — 1 test

56.10

 

 

 

65162

Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)

10.25

 

 

 

65165

Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell surface antigens using flow cytometric methods including (if performed) any test described in item  65069 or 65162

34.00

 

 

 

Group P2 — Chemical

66500

Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method except reagent tablet or reagent strip (with or without reflectance meter or electrophoresis) of: acetoacetate, acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, beta-hydroxybutyrate, bicarbonate, bilirubin (total), bilirubin (any fractions), C-reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, pyruvate, sodium, total protein, urate or urea — 1 test

9.55

 

 

 

66503

2 tests described in item 66500

11.60

 

 

 

66506

3 tests described in item 66500

13.65

 

 

 

66509

4 tests described in item 66500

15.70

 

 

 

66512

5 tests described in item 66500

17.75

 

 

 

66515

6 or more tests described in item 66500

19.80

 

 

 

66518

Investigation of cardiac or skeletal muscle damage by measurement of creatine kinase isoenzymes (by any method), troponin or myoglobin in plasma or serum — 1 or more tests in a 24 hour period

19.80

 

 

 

66521

Quantitation (except by reagent strip with or without reflectance meter or electrophoresis) of cholesterol or triglycerides or both in serum, plasma, urine or other body fluid

11.40

 

 

 

66524

A service described in item 66521 and 1 test described in item 66500

13.65

 

 

 

66527

A service described in item 66521 and 2 tests described in item 66500

15.70

 

 

 

66530

A service described in item 66521 and 3 tests described in item 66500

17.75

 

 

 

66533

A service described in item 66521 and 4 or more tests described in item 66500

19.80

 

 

 

66536

Quantitation of HDL cholesterol or apolipoprotein B/A1 ratio in a patient who:

(a)  has a serum cholesterol level >5.5mmol/L; or

(b)  has a fasting serum triglyceride level >2.0 mmol/L; or

(c)  is on a lipid lowering drug prescribed by a medical practitioner;

each episode to a maximum of 4 episodes in a 12 month period

(Item is subject to rule 9)

12.35

 

 

 

66539

Electrophoresis of serum for demonstration of lipoprotein subclasses, if the cholesterol is >6.5 mmol/L and triglyceride >4.0 mmol/L or in the diagnosis of types III and IV hyperlipidaema — each episode to a maximum of 2 episodes in a 12 month period

30.20

 

 

 

66542

Oral glucose tolerance test for the diagnosis of diabetes mellitus that includes the following:

(a)  administration of glucose;

(b)  at least 3 estimations of blood glucose;

(c)  (if performed) any test described in item 66695

17.70

 

 

 

66545

Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes:

(a)  administration of glucose; and

(b)  1 or 2 measurements of blood glucose; and

(c)  (if performed) any test in item 66695

1 patient episode in a pregnancy

13.60

 

 

 

66548

Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes:

(a)  administration of glucose; and

(b)  at least 3 measurements of blood glucose; and

(c)  (if performed) any test in item 66695

1 patient episode in a pregnancy

17.70

 

 

 

66551

Quantitation of glycosylated haemoglobin performed in the management of established diabetes — each test to a maximum of 4 tests in a 12 month period

16.60

 

 

 

66554

Quantitation of glycosylated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant — each test to a maximum of 6 tests in a 12 month period which includes the whole pregnancy, including a service in item 66551 (if performed)

16.60

 

 

 

66557

Quantitation of fructosamine performed in the management of established diabetes — each test to a maximum of 4 tests in a 12 month period

9.55

 

 

 

66560

Microalbumin in proven diabetes mellitus —  quantitation in urine — 1 or more tests

19.90

 

 

 

66563

Osmolality, estimation by osmometer, in serum or in urine — 1 or more tests

24.35

 

 

 

66566

Quantitation of:

(a)  blood gases (including pO2, oxygen saturation and pCO2 ); and

(b)  bicarbonate and pH;

including any other measurement (eg haemoglobin, potassium or ionised calcium) or calculation performed on the same specimen — 1 or more tests on 1 specimen

33.25

 

 

 

66569

Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed within any 1 day

42.05

 

 

 

66572

Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed within any 1 day

50.85

 

 

 

66575

Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed within any 1 day

59.65

 

 

 

66578

Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed within any 1 day

68.45

 

 

 

66581

Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed within any 1 day

77.25

 

 

 

66584

Quantitation of ionised calcium (except if performed as part of item 66566) — 1 test

9.55

 

 

 

66587

Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least 1 blood specimen

46.90

 

 

 

66590

Calculus, analysis of 1 or more

30.20

 

 

 

66593

Ferritin — quantitation, except if requested as part of iron studies

19.90

 

 

 

66596

Iron studies, consisting of quantitation of:

(a)  serum iron; and

(b)  transferrin or iron binding capacity; and

(c)  ferritin

36.70

 

 

 

66599

Serum B12 or serum folate — 1 or more tests within a 28 day period

24.35

 

 

 

66602

Red cell folate and serum B12 and, if required, serum folate, to a maximum of 3 episodes in a 12 month period

44.45

 

 

 

66605

Vitamins — quantitation of vitamins A, B1, B2, B3, B6, C and E in blood, urine or other body fluid — 1 or more tests  within a 6 month period

30.20

 

 

 

66608

Vitamin D or D fractions — 1 or more tests

41.70

 

 

 

66611

Quantitation, not elsewhere described in this table by any method or methods, in blood or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken — 1 test

(Item is subject to rule 6)

20.45

 

 

 

66614

2 tests described in item 66611

(Item is subject to rule 6)

28.65

 

 

 

66617

3 or more tests described in item 66611

(Item is subject to rule 6)

36.85

 

 

 

66620

Tests described in item 66611, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 — each test to a maximum of 2 tests

(Item is subject to rule 6)

8.20

 

 

 

66623

All qualitative and quantitative tests on blood, urine or other body fluid for:

(a)  a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or

(b)  ingested or absorbed toxic chemicals;

including a service described in item 66611, 66614 or 66617 (if performed), but excluding:

(c)  the surveillance of sports people and athletes for performance improving substances; and

(d)  the monitoring of patients participating in a drug abuse treatment program

41.00

 

 

 

66626

Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient:

(a)  participating in a drug abuse treatment program; or

(b)  being monitored for drug effects;

but excluding the surveillance of sports people and athletes for performance improving substances;

including all tests on blood, urine or other body fluid — each episode, to a maximum of 21 episodes in a 12 month period

23.80

 

 

 

66629

Beta-2-microglobulin — quantitation in serum, urine or other body fluids — 1 or more tests

19.90

 

 

 

66632

Caeruloplasmin, haptoglobins, or prealbumin — quantitation in serum, urine or other body fluids — 1 or more tests

19.90

 

 

 

66635

Alpha‑1‑antitrypsin — quantitation in serum, urine or other body fluid — 1 or more tests

19.90

 

 

 

66638

Isoelectric focussing or similar methods for determination of alpha‑1‑antitrypsin phenotype in serum — 1 or more tests

28.80

 

 

 

66641

Electrophoresis of serum or other body fluid to demonstrate:

(a)  the isoenzymes of lactate dehydrogenase; or

(b)  the isoenzymes of alkaline phosphatase;

including the preliminary quantitation of total relevant enzyme activity — 1 or more tests

28.80

 

 

 

66644

C-1 esterase inhibitor — quantitation

19.90

 

 

 

66647

C-1 esterase inhibitor — functional assay

44.50

 

 

 

66650

Alpha‑fetoprotein, CA‑15.3 antigen (CA15.3), CA‑125 antigen (CA125), CA‑19.9 antigen (CA19.9), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), mammary serum antigen (MSA), thyroglobulin in serum or other body fluid, in the monitoring of malignancy — quantitation — 1 test

20.50

 

 

 

66653

2 or more tests described in item 66650

37.75

 

 

 

66656

Prostate specific antigen or prostate acid phosphatase — quantitation in the confirmation or monitoring of malignancy — 1 test

19.90

 

 

 

66659

2 tests described in item 66656

36.65

 

 

 

66662

Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast — 1 or more tests

78.90

 

 

 

66665

Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period — each test

30.20

 

 

 

66668

Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium,  strontium, or zinc, in blood, urine or other body fluid or tissue — 1 or more tests in a 6 month period

36.40

 

 

 

66671

Quantitation of serum aluminium in a patient in a renal dialysis program — each test

36.40

 

 

 

66674

Quantitation of:

(a)  faecal fat; or

(b)  breath hydrogen in response to loading with disaccharides;

1 or more tests within a 28 day period

39.45

 

 

 

66677

Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old

11.00

 

 

 

66680

Quantitation of disaccharidases and other enzymes in intestinal tissue — 1 or more tests

73.45

 

 

 

66683

Enzymes — quantitation in solid tissue or tissues other than blood elements or intestinal tissue — 1 or more tests

73.45

 

 

 

66686

Performance of 1 or more of the following procedures:

(a)  growth hormone suppression by glucose loading;

(b)  growth hormone stimulation by exercise;

(c)  dexamethasone suppression test;

(d)  sweat collection by iontophoresis for chloride analysis;

(e)  pharmacological stimulation of growth hormone

50.00

 

 

 

66689

Personal performance by a recognised pathologist of 1 of the following procedures:

(a)  gonadotrophin releasing hormone stimulation test;

(b)  synacthen stimulation test;

(c)  glucagon stimulation test with C‑peptide measurement;

(d)  pentagastrin or calcium stimulation of thyrocalcitonin release;

(e)  secretin or calcium stimulation of gastrin release;

(f)   insulin hypoglycaemia;

(g)  arginine infusion;

(h)  thyrotrophin releasing hormone (TRH) test

80.00

 

 

 

66692

Personal performance by a recognised pathologist of 2 or more tests described in item 66689

140.00

 

 

 

66695

Quantitation of hormones and hormone binding proteins — ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF‑1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone) — 1 test

31.55

 

 

 

66698

2 tests described in item 66695

(Item is subject to rule 6)

42.55

 

 

 

66701

3 tests described in item 66695

(Item is subject to rule 6)

53.55

 

 

 

66704

4 tests described in item 66695

(Item is subject to rule 6)

64.55

 

 

 

66707

5 tests described in item 66695

(Item is subject to rule 6)

75.55

 

 

 

66710

6 or more tests described in item 66695

(Item is subject to rule 6)

86.55

 

 

 

66713

Tests described in item 66695, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 — each test to a maximum of 5 tests

(Item is subject to rule 6)

11.05

 

 

 

66716

TSH quantitation

31.55

 

 

 

66719

Thyroid function tests (comprising the service described in item 66716 and 1 or more of the following tests — estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) for a patient, if at least 1 of the following conditions is satisfied:

(a)  the patient has an abnormal level of TSH;

(b)  the tests are performed:

(i)    for the purpose of monitoring thyroid disease in the patient; or

(ii)   to investigate the sick euthyroid syndrome if the patient is an admitted patient; or

(iii)  to investigate dementia or psychiatric illness of the patient; or

(iv)  to investigate amenorrhoea or infertility of the patient;

(c)  the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction;

(d)  the patient is on drugs that interfere with thyroid hormone metabolism or function

(Item is subject to rule 10)

41.00

 

 

 

66722

TSH quantitation described in item 66716 and 1 test described in item 66695

(Item is subject to rule 6)

42.55

 

 

 

66725

TSH quantitation described in item 66716 and 2 tests described in item 66695

(Item is subject to rule 6)

53.55

 

 

 

66728

TSH quantitation described in item 66716 and 3 tests described in item 66695

(Item is subject to rule 6)

64.55

 

 

 

66731

TSH quantitation described in item 66716 and 4 tests described in item 66695

(Item is subject to rule 6)

75.55

 

 

 

66734

TSH quantitation described in item 66716 and 5 tests described in item 66695

(Item is subject to rule 6)

86.55

 

 

 

66737

Tests described in items 66716 and 66695, if rendered under a request mentioned in subparagraph (2) (a) (iii) of rule 6 — each test to a maximum of 5 tests

(Item is subject to rule 6)

11.05

 

 

 

66740

Quantitation, in pregnancy, of alpha-fetoprotein, human chorionic gonadotrophin, oestriol and any other substance to detect foetal abnormality, including a service described in 1 or more of items 66743, 66746, 73527 and 73529 (if performed) — 1 patient episode in a pregnancy

54.50

 

 

 

66743

Quantitation of alpha-fetoprotein in serum or other body fluids during pregnancy except if requested as part of item 66740

19.90

 

 

 

66746

Human placental lactogen or oestriol-quantitation, except if requested as part of item 66740 — 1 test

31.55

 

 

 

66749

Amniotic fluid, spectrophotometric examination of, and quantitation of:

(a)  lecithin/sphingomyelin ratio; or

(b)  palmitic acid, phosphatidylglycerol orlamellar body phospholipid; or

(c)  bilirubin, including correction for haemoglobin

1 or more tests

32.50

 

 

 

66752

Quantitation of citrate, oxalate, total free fatty acids or amino acids including cysteine, homocysteine, cystine and hydroxyproline (except if performed as part of item 66773 or 66776) — 1 test

24.35

 

 

 

66755

2 or more tests described in item 66752

38.30

 

 

 

66758

Quantitation of angiotensin converting enzyme, or cholinesterase — 1 or more tests

24.35

 

 

 

66761

Test for reducing substances in faeces by any method (except reagent strip or dipstick)

13.00

 

 

 

66764

Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by:

(a)  an immunological method; and

(b)  a chemical method (except reagent strip or dip stick);

with a maximum of 3 examinations on specimens collected on separate days in a 28 day period — 1 examination by both methods

8.80

 

 

 

66767

2 examinations by both methods described in item 66764 performed on separately collected and identified specimens

17.60

 

 

 

66770

3 examinations by both methods described in item 66764 performed on separately collected and identified specimens

26.40

 

 

 

66773

Quantitation of products of collagen breakdown for the monitoring of patients with proven low bone mineral density, and if performed, a service described in item 66752 — 1 or more tests

24.35

 

 

 

66776

Quantitation of products of collagen breakdown for the monitoring of patients with metabolic bone disease or Paget’s disease of bone, and if performed, a service described in item 66752 — 1 or more tests

24.35

 

 

 

66779

Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin — quantitation — 1 or more tests

39.45

 

 

 

66782

Porphyrins or porphyrins precursors — detection in plasma, red cells, urine or faeces — 1 or more tests

13.00

 

 

 

66785

Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 1 test

39.45

 

 

 

66788

Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 2 or more tests

65.00

 

 

 

66791

Porphyrin biosynthetic enzymes — measurement of activity in blood cells or other tissues — 1 or more tests

73.45

 

 

 

66794

Detection of the C282Y genetic mutation for haemochromatosis where:

(a)  the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or

(b)  the patient has a first degree relative with haemochromatosis or with homozygosity for the C282Y genetic mutation;

not exceeding 1 episode in a 3 year period

(Item is subject to rule 22)

36.00

 

 

 

Group P3 — Microbiology

69300

Microscopy of wet film material other  than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:

(a)  differential cell count (if performed); or

(b)  examination for dermatophytes; or

(c)  dark ground illumination; or

(d)  stained preparation or preparations using any relevant stain or stains;

1 or more tests

12.20

 

 

 

69303

Culture and (if performed) microscopy to detect pathogenic micro‑organisms (including fungi but excluding viruses) from nasal swabs, throat swabs, eye swabs and ear swabs (excluding swabs taken for epidemiological surveillance), including (if performed):

(a)  pathogen identification and antibiotic susceptibility testing; or

(b)  the detection of antigens not elsewhere described in this table; or

(c)  a service described in item 69300;

specimens from 1 or more sites

21.50

 

 

 

69306

Microscopy and culture to detect pathogenic micro-organisms (including fungi but excluding viruses) from skin or other superficial sites, including (if performed):

(a)  the detection of antigens not elsewhere specified in this table; or

(b)  pathogen identification and antibiotic susceptibility testing; or

(c)  a service described in items 69300, 69303, 69312, 69318 and 73810;

1 or more tests on 1 or more specimens

33.00

 

 

 

69309

Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed):

(a)  the detection of antigens not elsewhere specified in this table; or

(b)  a service described in items 69300, 69303, 69306, 69312, 69318 and 73810;

1 or more tests on 1 or more specimens

47.00

 

 

 

69312

Microscopy and culture to detect pathogenic micro‑organisms (including fungi but excluding viruses) from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed):

(a)  the detection of antigens not elsewhere specified in this table; or

(b)  pathogen identification and antibiotic susceptibility testing; or

(c)  a service described in items 69300, 69303, 69306 and 69318;

1 or more tests on 1 or more specimens

33.00

 

 

 

69315

Microscopy and culture to detect pathogenic micro‑organisms, including the detection of chlamydia by any method from urethra, vagina, cervix or rectum and including (if performed):

(a)  the detection of microbial antigens; or

(b)  pathogen identification and antibiotic susceptibility testing; or

(c)  a service described in item 69300, 69303, 69306, 69312, 69318, 69363, 69369, 69372, 69375 or 73810;

1 or more tests on 1 or more specimens

64.00

 

 

 

69318

Microscopy and culture to detect pathogenic micro‑organisms (including fungi but excluding viruses) from specimens of sputum (except when part of items 69324, 69327, 69330), including (if performed):

(a)  the detection of antigens not elsewhere specified in this table; or

(b)  pathogen identification and antibiotic susceptibility testing; or

(c)  a service described in items 69300, 69303, 69306 and 69312;

1 or more tests on 1 or more specimens

33.00

 

 

 

69321

Microscopy and culture of post-operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic culture and the use of different culture media, and including (if performed):

(a)  pathogen identification and antibiotic susceptibility testing; or

(b)  the detection of antigens not elsewhere specified in this table; or

(c)  a service described in item 69300, 69303 or 69306, 69312 or 69318;

specimens from 1 or more sites

47.00

 

 

 

69324

Microscopy with appropriate stains and culture of 1 specimen of sputum, urine, other body fluids or operative or biopsy specimens for mycobacteria including (if performed):

(a)  microscopy and culture of other bacterial pathogens; or

(b)  pathogen identification and antibiotic susceptibility testing;

including a service described in item 69300

42.00

 

 

 

69327

Microscopy with appropriate stains and culture of 2 specimens of sputum, urine, other body fluids or operative or biopsy specimens for mycobacteria including (if performed):

(a)  microscopy and culture of other bacterial pathogens; or

(b)  pathogen identification and antibiotic susceptibility testing;

including a service described in item 69300

83.00

 

 

 

69330

Microscopy with appropriate stains and culture of 3 specimens of sputum, urine, other body fluids or operative or biopsy specimens for mycobacteria including (if performed):

(a)  microscopy and culture of other bacterial pathogens; or

(b)  pathogen identification and antibiotic susceptibility testing;

including a service described in item 69300

125.00

 

 

 

69333

Urine examination (including serial examination) by any means other than simple culture by dip slide, including:

(a)  cell count; and

(b)  culture; and

(c)  colony count; and

(d)  (if performed) stained preparations; and

(e)  (if performed) identification of cultured pathogens; and

(f)   (if performed) antibiotic susceptibility testing; and

(g)  (if performed) examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts

20.55

 

 

 

69336

Microscopy of faeces for parasites using concentration techniques (including the use of appropriate stains) with a maximum of 3 examinations on specimens collected on separate days, including (if performed) a service described in item 69300 — 1 examination

18.65

 

 

 

69339

2 examinations described in item 69336 performed on separately collected and identified specimens

37.25

 

 

 

69342

3 examinations described in item 69336 performed on separately collected and identified specimens

55.90

 

 

 

69345

Culture of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed):

(a)  pathogen identification and antibiotic susceptibility testing; and

(b)  the detection of clostridial toxins or antigens not elsewhere specified in this table; and

(c)  a service described in item 69300;

with a maximum of 3 examinations performed on separately collected and identified specimens in any 7 day period — 1 examination

51.65

 

 

 

69348

2 examinations described in item 69345 performed on separately collected and identified specimens

103.30

 

 

 

69351

3 examinations described in item 69345 performed on separately collected and identified specimens

154.95

 

 

 

69354

Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed):

(a)  identification of any cultured pathogen; and

(b)  necessary antibiotic susceptibility testing;

to a maximum of 3 sets of cultures — 1 set of cultures

30.00

 

 

 

69357

2 sets of cultures described in item 69354

60.00

 

 

 

69360

3 sets of cultures described in item 69354

90.00

 

 

 

69363

Detection of clostridium difficile or clostridium difficile toxin (except if a service described in items 69345, 69348, 69351, 69369 or 69372 has been performed) — 1 or more tests

25.00

 

 

 

69366

Test for Helicobacter pylori in faeces, for either:

(a)  the confirmation of Helicobacter pylori colonisation:

(i)    where suitable biopsy material for diagnosis cannot be obtained at endoscopy in patients with peptic ulcer disease, or where the diagnosis of peptic ulcer has been made on barium meal; or

(ii)   in patients with a history of peptic ulcer disease or gastric neoplasia,  where endoscopy is not indicated; or

(b)  the monitoring of the success of eradication  therapy for Helicobacter pylori in patients with peptic ulcer disease;

where any request for the test by a medical practitioner specifically identifies in writing one or more of the clinical indications for the test

34.10

 

 

 

69369

Detection of chlamydia by any method in specimens from 1 or more sites

27.80

 

 

 

69372

Detection of microbial antigens (except if the service described in item 69369 has been performed) — 1 or more tests

25.00

 

 

 

69375

Examination for Herpes simplex virus, varicella zoster virus and cytomegalovirus by culture, including a service described in item 69315, 69369 or 69372 (if performed)

28.20

 

 

 

69378

Quantitation of HIV viral RNA load in plasma, serum or cerebrospinal fluid in the monitoring of a HIV sero‑positive patient, who is not on antiretroviral therapy — 1 or more assays on 1 or more specimens in any 1 episode to a maximum of 6 episodes in a 12 month period

(Item is subject to rule 20)

176.00

 

 

 

69381

Quantitation of HIV viral RNA load in plasma, serum or cerebrospinal fluid in the monitoring of antiretroviral therapy in a HIV sero‑positive patient — 1 or more assays on 1 or more specimens in any 1 episode to a maximum of 6 episodes in a 12 month period

(Item is subject to rule 20)

176.00

 

 

 

69384

Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in the Schedule — 1 test

(Item is subject to rule 6)

15.30

 

 

 

69387

2 tests described in item 69384

(Item is subject to rule 6)

27.15

 

 

 

69390

3 tests described in item 69384

(Item is subject to rule 6)

38.15

 

 

 

69393

4 tests described in item 69384

(Item is subject to rule 6)

49.15

 

 

 

69396

5 tests described in item 69384

(Item is subject to rule 6)

60.15

 

 

 

69399

6 or more tests described in item 69384

71.15

 

 

 

69402

Tests described in item 69384, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 — each test to a maximum of 5 tests

(Item is subject to rule 6)

10.80

 

 

 

69405

Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:

(a)  the determination of 1 of the following: rubella immune status, specific syphilis serology, hepatitis B surface antigen; and

(b)  (if performed) a service described in 1 or more of items 69384, 69414 to 69435, 69447 to 69456, 69462 and 69465

15.30

 

 

 

69408

Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:

(a)  the determination of 2 of the following — rubella immune status, specific syphilis serology or, hepatitis B surface antigen; and

(b)  (if performed) a service described in 1 or more of items 69384, 69414 to 69435, 69447 to 69456, 69462 and 69465

27.15

 

 

 

69411

Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:

(a)  the determination of all 3 of the following: rubella immune status, specific syphilis serology and, Hepatitis B surface antigen; and

(b)  (if performed) a service described in 1 or more of items 69384, 69414 to 69435, 69447 to 69456, 69462 and 69465

38.15

 

 

 

69414

Investigation for acute Hepatitis A using:

       Hepatitis A IgM antibody test

(Item is subject to rule 12)

15.30

 

 

 

69417

Determination of immune status to Hepatitis A using:

       Hepatitis A IgG antibody test

(Item is subject to rule 12)

15.30

 

 

 

69420

Investigation for acute or resolving Hepatitis B, or testing of close, recent contacts of proven Hepatitis B infection, including:

(a)  Hepatitis B surface antigen test; and

(b)  Hepatitis B core antibody test; and

(c)  if performed, Hepatitis B e antibody test (where the Hepatitis B surface antigen test is negative and Hepatitis B core antibody test is positive)

(Item is subject to rule 12)

27.15

 

 

 

69423

Investigation for resolution of Hepatitis B if the Hepatitis B core antibody test is positive and the Hepatitis B surface antigen test is negative, including:

(a)  Hepatitis B core antibody test; and

(b)  Hepatitis B surface antigen test; and

(c)  Hepatitis B surface antibody test

(Item is subject to rule 12)

38.15

 

 

 

69426

Determination of immune status to Hepatitis B (post exposure) using:

        Hepatitis B core antibody test

(Item is subject to rule 12)

15.30

 

 

 

69429

Determination of immune status to Hepatitis B (post vaccination) using:

        Hepatitis B surface antibody test 

(Item is subject to rule 12)

15.30

 

 

 

69432

Investigation for chronic Hepatitis B or determination of carriage of Hepatitis B antigen using:

        Hepatitis B surface antigen test

(Item is subject to rule 12)

15.30

 

 

 

69435

Investigation for chronic Hepatitis B or carriage of Hepatitis B antigen if the Hepatitis B surface antigen test is positive, including:

(a)  Hepatitis B surface antigen test; and

(b)  Hepatitis B e antigen test

(Item is subject to rule 12)

27.15

 

 

 

69438

Testing for Hepatitis C using:

        Hepatitis C antibody test

(Item is subject to rule 12)

16.70

 

 

 

69441

Supplementary testing for Hepatitis C antibodies using a different Hepatitis C antibody assay on the specimen which has a reactive result on the initial Hepatitis C antibody test

(Item is not subject to rule 12)

16.70

 

 

 

69444

Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied:

(a)  the patient is Hepatitis C sero‑positive and has normal liver function tests on 2 occasions at least 6 months apart;

(b)  the patient’s serological status is uncertain after testing;

(c)  the test is performed for the purpose of:

(i)    determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or

(ii)   the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient;

not exceeding 1 episode in a 12 month period

(Item is subject to rule 21)

90.00

 

 

 

69447

Investigation for acute or chronic Hepatitis D in a patient with a positive Hepatitis B surface antigen test using:

        Hepatitis D antibody test

(Item is subject to rule 12)

15.30

 

 

 

69450

Determination of immune status to Hepatitis A and Hepatitis B, including:

(a)  Hepatitis A IgG antibody test; and

(b)  Hepatitis B core antibody test or Hepatitis B surface antibody test

(Item is subject to rule 12)

27.15

 

 

 

69453

Investigation for chronic viral hepatitis, or Hepatitis B or Hepatitis C carriage, including:

(a)  Hepatitis B surface antigen test; and

(b)  Hepatitis C antibody test

(Item is subject to rule 12)

28.55

 

 

 

69456

Investigation for chronic viral hepatitis, or Hepatitis B or Hepatitis C carriage, if Hepatitis B surface antigen test is positive, including:

(a)  Hepatitis C antibody test; and

(b)  Hepatitis B surface antigen test; and

(c)  Hepatitis B e antigen test

(Item is subject to rule 12)

39.55

 

 

 

69459

Investigation for acute Hepatitis A, Hepatitis B, Hepatitis C and Hepatitis D in a patient with a currently elevated transaminase level, including:

(a)  Hepatitis A IgM antibody test; and

(b)  Hepatitis C antibody test; and

(c)  Hepatitis B surface antigen test; and

(d)  Hepatitis B core antibody test; and

(e)  if performed, Hepatitis B e antibody test (if Hepatitis B surface antigen test is negative and Hepatitis B core antibody test is positive); and

(f)   if performed, Hepatitis D antibody test (if Hepatitis B surface antigen test is positive)

(Item is subject to rule 12)

50.55

 

 

 

69462

Determination of immune status to Hepatitis B and testing for Hepatitis C, including:

(a)  Hepatitis C antibody test; and

(b)  Hepatitis B core antibody test or Hepatitis B surface antibody test

(Item is subject to rule 12)

28.55

 

 

 

69465

Syphilis serology and any 1 of item 69435, 69438 or 69453

(Item is subject to rule 12)

38.15

 

 

 

69468

Investigation for acute Hepatitis A and Hepatitis C in a patient with a currently elevated transaminase level, including:

(a)  Hepatitis A IgM antibody test; and

(b)  Hepatitis C antibody test

(Item subject to rule 12)

30.20

 

 

 

69471

Test of cell‑mediated immunity in blood for the detection of active tuberculosis or atypical mycobacterial infection in an immunosuppressed or immunocompromised patient — 1 test

34.10

 

 

 

Group P4 — Immunology

71057

Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate:

(a)  protein classes; or

(b)  presence and amount of paraprotein;

including the preliminary quantitation of total protein, albmin and globulin — 1 specimen type

35.20

 

 

 

71058

Examination as described in item 71057 of 2 or more specimen types

49.85

 

 

 

71059

Electrophoresis and immunofixation or immuno electrophoresis or isoelectric focussing of:

(a)  urine for detection of Bence Jones proteins; and 

(b)  serum, plasma or other body fluid;

and characerisation, if detected, of a paraprotein or cryoglobulin not previously characterised — examination of 1 specimen type (eg serum, urine or CSF)

28.80

 

 

 

71060

Examination as described in item 71059 of 2 or more specimen types

43.45

71062

Electrophoresis and immunofixation or immuno electrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient’s serum for comparison purposes — 1 or more tests

43.45

 

 

 

71064

Detection and quantitation of cryoglobulins or cryofibrinogen — 1 or more tests

20.45

 

 

 

71067

Quantitation of total immunoglobulins A, G, M or D by any method in serum, urine or other body fluid — 1 test

14.85

 

 

 

71069

2 tests described in item 71067

23.45

 

 

 

71071

3 or more tests described in item 71067

32.05

 

 

 

71073

Quantitation of all 4 immunoglobulin G subclasses — each patient episode

104.75

 

 

 

71075

Quantitation of immunoglobulin E (total), with a maximum of 2 patient episodes in any 12 month period — each patient episode

26.70

 

 

 

71077

Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6 patient episodes in a 12 month period — each patient episode

26.70

 

 

 

71079

Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period — each patient episode

26.50

 

 

 

71081

Quantitation of total haemolytic complement

19.90

 

 

 

71083

Quantitation of complement components C3 and C4 or properdin factor B — 1 test

19.90

 

 

 

71085

2 tests described in item 71083

28.55

 

 

 

71087

3 or more tests described in item 71083

37.20

 

 

 

71089

Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule — 1 test

28.75

 

 

 

71091

2 tests described in item 71089

52.10

 

 

 

71093

3 or more tests described in item 71089

75.45

 

 

 

71095

Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years

40.00

 

 

 

71097

Antinuclear antibodies — detection in serum or other body fluids, including quantitation if required

25.10

 

 

 

71099

Double-stranded DNA antibodies — quantitation by 1 or more methods other than the Crithidia method

26.20

 

 

 

71101

Antibodies to 1 or more extractable nuclear antigens — detection in serum or other body fluids

17.15

 

 

 

71103

Characterisation of an antibody detected in a service described in item 71101 (including that service)

51.35

 

 

 

71106

Rheumatoid factor — detection by any technique in serum or other body fluids, including quantitation if required

11.15

 

 

 

71109

Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, glomerular basement membrane, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, neutrophil cytoplasm, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) — detection, including quantitation if required, of 1 antibody

34.10

 

 

 

71113

Detection of 2 antibodies described in item 71109

46.80

 

 

 

71115

Detection of 3 antibodies described in item 71109

59.50

 

 

 

71117

Detection of 4 antibodies described in item 71109

72.20

 

 

 

71119

Antibodies to tissue antigens not elsewhere specified in this table — detection, including quantitation if required, of 1 antibody

17.10

 

 

 

71121

Detection of 2 antibodies specified in item 71119

20.50

 

 

 

71123

Detection of 3 antibodies specified in item 71119

23.90

 

 

 

71125

Detection of 4 or more antibodies specified in item 71119

27.30

 

 

 

71127

Functional tests for lymphocytes — quantitation other than by microscopy of:

(a)  proliferation induced by 1 or more mitogens; or

(b)  proliferation induced by 1 or more antigens; or

(c)  estimation of 1 or more mixed lymphocyte reactions;

including a test described in item 65063 or 65066 (if performed), with a maximum of 2 patient episodes in a 12 month period — each patient episode

174.05

 

 

 

71129

2 tests described in item 71127

215.00

 

 

 

71131

3 or more tests described in item 71127

255.95

 

 

 

71135

Quantitation of neutrophil function, comprising at least 2 of the following:

(a)  chemotaxis;

(b)  phagocytosis;

(c)  oxidative metabolism;

(d)  bactericidal activity;

including any test described in item 65063 or 65066 (other than nitroblue tetrazolium reduction slide test), with a maximum of 2 patient episodes in a 12 month period — each patient episode

205.25

 

 

 

71137

Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, with a maximum of 2 patient episodes in a 12 month period — each patient episode

29.85

 

 

 

71139

Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid

102.65

 

 

 

71141

Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens

194.80

 

 

 

71143

Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue

256.60

 

 

 

71145

Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed) on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid

418.95

 

 

 

71147

HLA-B27 typing

40.00

 

 

 

71149

Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147

106.85

 

 

 

71151

Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) — phenotyping or genotyping of 2 or more antigens

117.30

 

 

 

Group P5 — Tissue pathology

72813

Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens

(Item is subject to rule 14)

79.00

 

 

 

72816

Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen

(Item is subject to rule 14)

84.50

 

 

 

72817

Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 or more separately identified specimens

(Item is subject to rule 14)

94.50

 

 

 

72823

Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen

(Item is subject to rule 14)

95.00

 

 

 

72824

Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 to 4 separately identified specimens

(Item is subject to rule 14)

126.00

 

 

 

72825

Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 5 or more separately identified specimens

(Item is subject to rule 14)

161.00

 

 

 

72830

Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens

(Item is subject to rule 14)

150.00

 

 

 

72836

Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens

(Item is subject to rule 14)

180.00

 

 

 

72844

Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system — 1 or more tests

30.00

 

 

 

72846

Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies

(Item is subject to rule 14)

42.00

 

 

 

72847

Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies

(Item is subject to rule 14)

56.00

 

 

 

72851

Electron microscopic examination of biopsy material — 1 separately identified specimen

(Item is subject to rule 14)

180.00

 

 

 

72852

Electron microscopic examination of biopsy material — 2 or more separately identified specimens

(Item is subject to rule 14)

240.00

 

 

 

72855

Intraoperative frozen section diagnosis of biopsy material — 1 separately identified specimen

(Item is subject to rule 14)

180.00

 

 

 

72856

Intraoperative frozen section diagnosis of biopsy material — 2 or more separately identified specimens

(Item is subject to rule 14)

240.00

 

 

 

Group P6 — Cytology

73043

Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes — 1 or more tests

19.80

 

 

 

73045

Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053); and including any Group P5 service (if performed) on:

(a)  specimens resulting from washings or brushings from sites not specified in item 73043; or

(b)  a single specimen of sputum or urine; or

(c)  1 or more specimens of other body fluids;

1 or more tests

45.00

 

 

 

73047

Cytology of a series of 3 sputum or urine specimens for malignant cells

90.00

 

 

 

73049

Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues

65.00

 

 

 

73051

Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues if:

(a)  the aspiration is performed by a recognised pathologist; or

(b)  a recognised pathologist attends the aspiration and performs cytological examination during the attendance

163.85

 

 

 

73053

Cytology of smears from cervix:

(a)  for detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or

(b)  due to an unsatisfactory smear taken in the circumstances defined in paragraph (a) above; or

(c)  if there is inadequate information provided to use item 73055;

each examination

17.80

 

 

 

73055

Cytology not associated with item 73053, of smears from cervix in association with:

(a)  the management of previously detected abnormalities including precancerous or cancerous conditions; or

(b)  the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia;

each test

17.80

 

 

 

73057

Cytology of smears from vagina, not associated with item 73053 or 73055 nor to monitor hormone replacement therapy — each test

17.80

 

 

 

73059

Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies

42.00

 

 

 

73060

Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies

56.00

 

 

 

Group P7 — Cytogenetics

73287

Chromosome studies, including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of 1 or more of any tissue or fluid except blood — 1 or more tests

344.00

 

 

 

73289

Chromosome studies, including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of blood — 1 or more tests

311.70

 

 

 

Group P8 — Infertility and  pregnancy tests

73521

Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test)

9.50

 

 

 

73523

Semen examination (other than post-vasectomy semen examination), including:

(a)  measurement of volume, sperm count and motility; and

(b)  examination of stained preparations; and

(c)  morphology; and

(d)  (if performed) differential count and 1 or more chemical tests;

with a maximum of 4 episodes in a 12 month period — each episode

41.20

 

 

 

73525

Sperm antibodies — sperm-penetrating ability — 1 or more tests

18.20

 

 

 

73527

Chorionic gonadotrophin (beta‑HCG) — detection in serum or urine by 1 or more methods, including serial dilution (if performed) for diagnosis of pregnancy — 1 or more tests

9.90

 

 

 

73529

Chorionic gonadotrophin (beta‑HCG), quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of hydatidiform mole, HCG-secreting neoplasm, or threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527 — 1 test

28.25

 

 

 

Group P9 — Simple basic pathology tests

73801

Semen examination for presence of spermatozoa

6.75

 

 

 

73802

Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count — 1 test

4.45

 

 

 

73803

2 tests described in item 73802

6.20

 

 

 

73804

3 or more tests described in item 73802

7.95

 

 

 

73805

Microscopy of urine, whether stained or not, or catalase test

4.45

 

 

 

73806

Pregnancy test by 1 or more immunochemical methods

9.90

 

 

 

73807

Microscopy for wet film other than urine, including any relevant stain

6.75

 

 

 

73808

Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807

8.45

 

 

 

73809

Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method

2.30

 

 

 

73810

Microscopy for fungi in skin, hair or nails — 1 or more sites

6.75

 

 

 

73811

Mantoux test

10.95

 

 

 

Group P10 — Patient episode initiation

73901

Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory

7.95

 

 

 

73903

Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 from a person who is an in-patient of a hospital other than a recognised hospital

14.15

 

 

 

73905

Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital

7.85

 

 

 

73907

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected in a licensed collection centre

17.00

 

 

 

73909

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital

17.00

 

 

 

73910

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing

10.35

 

 

 

73912

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a nursing home or institution

17.00

 

 

 

73913

Initiation of a patient episode by collection of a specimen for a service (other than a service described in items 73901, 73903, 73905, 73907 or items in Group P9) if the specimen is collected from the person by the person

10.35

 

 

 

73915

Initiation of a patient episode by collection of a specimen for a service (other than a service described in items 73901, 73903, 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner

10.35

 

 

 

Group P11 — Specimen referred

73921

Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another approved pathology authority

(Item is subject to subrule 15 (9))

10.35

Part 3          Abbreviations

 

Test

Abbreviation

Item

Abnormal haemoglobins

AH

65117

Acid phosphatase

ACP

66500

Acetoacetate

ACAT

66500

Acetylcholine receptor — tissue antigens — antibodies

ARA

71109

Actinomycetes — microbial antibody testing

ACT

69384

Activated Protein C resistance

APC

65141

Adenovirus — microbial antibody testing

ADE

69384

Adrenal cortex — tissue antigens — antibodies

ADR

71109

Adrenocorticotrophic hormone (ACTH)

ACTH

66695

AFB microscopy & culture of sputum

AFB

69324-30

Alanine aminotransferase

ALT

66500

Albumin

ALB

66500

Alcohol (ethanol)

ETOH

 66626

Aldosterone

ALDS

66695

Alkaline phosphatase

ALP

66500

Alkaline phosphatase — isoenzymes

ALPI

66641

Alpha-1-antitrypsin

AAT

66635

Alpha-fetoprotein

AFP

66743

Alpha-fetoprotein — for Down’s syndrome and neural tube defect testing

NTDD

66740

Aluminium

AL

66668

Aluminium — renal dialysis

ALR

66671

Amino acids

AA

66752

Amiodarone

AMIO

66611

Amitriptyline

AMIT

66611

Ammonia

NH3

66500

Amniotic fluid examination

AFE

66749

Amylase

AMS

66500

Amylobarb

AMYL

66611

Androstenedione

ANDR

66695

Angiotensin converting enzyme

ACE

66758

Antibiotic & antimicrobial chemotherapeutic agents — quantitation

QAA

66611

Antibodies to extractable nuclear antigens — characterisation of antibodies if positive ENA

ENAP

71103

Antibodies to extractable nuclear antigens — detection

ENA

71101

Antibodies to nuclear antigens — detection

ANA

71097

Antibodies to nuclear antigens — quantitation & measurement of DNA binding if positive ANA

ANAP

71099

Antibodies to tissue antigens — acetylcholine receptor

ARA

71109

Antibodies to tissue antigens — adrenal cortex

ADR

71109

Antibodies to tissue antigens — cardiolipin

ACL

71109

Antibodies to tissue antigens — centromere

ACA

71119

Antibodies to tissue antigens — gastric parietal cell

PCA

71119

Antibodies to tissue antigens — gliadin IgA

GLIA

71119

Antibodies to tissue antigens — glomerular basement membrane

GBA

71109

Antibodies to tissue antigens — heart

AHE

71109

Antibodies to tissue antigens — histone

AHI

71109

Antibodies to tissue antigens — insulin receptor antibodies

INSA

71109

Antibodies to tissue antigens — intercellular cement substance of skin

ICCS

71109

Antibodies to tissue antigens — intrinsic factor

AIF

71109

Antibodies to tissue antigens — islet cell

AIC

71109

Antibodies to tissue antigens — Jo-1

JO1

71119

Antibodies to tissue antigens — keratin

KERA

71119

Antibodies to tissue antigens — liver/kidney microsomes

LKA

71119

Antibodies to tissue antigens — lymphocyte

ALY

71109

Antibodies to tissue antigens — mitochondria

MA

71119

Antibodies to tissue antigens — neuron

ANE

71109

Antibodies to tissue antigens — neutrophil cytoplasm

ANCA

71109

Antibodies to tissue antigens — ovary

AOV

71109

Antibodies to tissue antigens — parathyroid

PTHA

71109

Antibodies to tissue antigens — platelet

APA

71109

Antibodies to tissue antigens — PM-Sc1

PM1

71119

Antibodies to tissue antigens — reticulin

RCA

71119

Antibodies to tissue antigens — salivary gland

ASG

71109

Antibodies to tissue antigens — Scl-70

SCL

71119

Antibodies to tissue antigens — skeletal muscle

SLA

71109

Antibodies to tissue antigens — skin basement membrane

SKA

71109

Antibodies to tissue antigens — smooth muscle

SMA

71119

Antibodies to tissue antigens — thyroglobulin

ATG

71109

Antibodies to tissue antigens — thyroid microsome

TMA

71109

Antibodies to tissue antigens — TSH receptor antibody test

TSHA

71109

Antibody testing, microbial (see Microbial)

 

 

Antigen testing, microbial (see Microbial)

 

 

Antithrombin III

ATH

65132

Anus — cytology on specimens from

SMCY

73043

Apolipoprotein B/A1 ratio

APO

66536

Arginine infusion

ARIN

66689

Arsenic

AS

66668

Aspartate aminotransferase

AST

66500

Aspergillus — microbial antibody testing

ASP

69384

Avian precipitins (bird fancier’s disease) — microbial antibody testing

APP

69384

B12 vitamin

RCF

66602

Barbiturate

BARB

66611

Beryllium

BE

66668

Beta-2-microglobulin

BMIC

66629

Beta-hydroxybutyrate

BHYB

66500

Bicarbonate

HCO3

66500

Bilirubin (all fractions)

BILI

66500

Bilirubin (all fractions) — in urine

UBIL

66500

Bilirubin (all fractions) — neonatal

BILN

66749

Bird fancier’s disease (see avian precipitins)

APP

69384

Blastomyces — microbial antibody testing

BLM

69384

Blood — compatability testing

XMAT

65099-108

Blood — culture

BC

69354-60

Blood — faecal occult

FOB

66764-70

Blood — film

BF

65066

Blood — full examination

FBE

65069

Blood — gases

GAS

66566

Blood — group & blood group antibodies

BGAB

65096

Blood — group antibodies

BGA

65111

Blood — group systems

BGS

65093

Blood — grouping — ABO & RH (D antigen)

BG

65090

Blood — viscosity

VISC

65060

Body cavities — aspirations of — microscopy & culture of material from

MCS3

69321

Body fluids — cytology

BFCY

73045

Bone — low mineral densities

CBLB

66773

Bone — metabolic bone disease

CBMB

66776

Bone marrow examination — aspirate

BMEA

65087

Bone marrow examination — trephine

BMET

65084

Bordetella pertussis — microbial antibody testing

BOR

69384

Borrelia burgdorferi — microbial antibody testing

BOB

69384

Breath hydrogen test

BHT

66674

Bromide

BRMD

66611

Brucella — microbial antibody testing 

BRU

69384

C-l esterase inhibitor — functional

CEIF

66647

C-l esterase inhibitor — quantitation

CEIQ

66644

CA-125 antigen

C125

66650

CA-15.3 antigen

CA15

66650

Cadmium

CD

66668

Caeruloplasmin

CPLS

66632

CA-l9.9 antigen

CA19

66650

Calcitonin

CALT

66695

Calcium (total or corrected for albumin)

CA

66500

Calculus analysis

CALC

66590

Campylobacter jejuni — microbial antibody testing

CAM

69384

Candida — microbial antibody testing

CAN

69384

Carbamazepine (Tegretol)

CARB

66611

Carboxyhaemaglobin

COHB

65117

Carcinoembryonic antigen

CEA

66650

Cardiac enzymes (see group tests in Division A)

CE

66506

Cardiolipin — tissue antigens — antibodies

ACL

71109

Catecholamines

CAT

66779

Cell mediated immunity — delayed type — hypersensitivity test

CMI

71137

Cell-mediated immunity in blood

CMIB

69471

Centromere — tissue antigens — antibodies

ACA

71119

Cervix —  cytology — abnormalities

CCRA

73055

Cervix — cytology — routine

CCR

73053

Cervix — microscopy & culture of material from

MCS2

69312-15

Characterisation of antibodies if positive ENA

ENAP

71103

Chemicals, toxic (ingested or absorbed) — assays

DRGO

66623

Chlamydia — investigation by any method

CHLM

69369

Chlamydia — microbial antibody testing

CHL

69384

Chlamydia — microbial antigen testing

CHLY

69315, 69369

Chloral hydrate

CHHY

66611

Chlorazepate

CHZP

66611

Chloride

CL

66500

Chloroquine

CLOQ

66611

Chlorpromazine

CHLO

66611

Cholesterol

CHOL

66521

Cholesterol — HDL

HDLC

66536

Cholinesterase

CHSE

66758

Chorionic gonadotrophin — for diagnosis of specified conditions

HCGD

73529

Chorionic gonadotrophin — for Down’s syndrome and neural tube defect testing

NTDD

66740

Chorionic gonadotrophin — for pregnancy diagnosis

HCG

73527

Chromium

CR

66668

Chromosome identification — studies — blood

CSB

73289

Chromosome identification — studies — other than blood

CS

73287

Chromosome identification and banding

 

73287-89  

Cimetidine

CMTD

66611

Clobazam

CLOB

66611

Clomipramine

CLOM

66611

Clonazepam (Rivotril)

CLON

66611

Clostridium difficile — microbial antigen testing

CLDT

69363

Coagulation — factors (see individual factors)

 

 

Coagulation — studies (see group tests in Division A)

COAG

65120

Coccidioides — microbial antibody testing  

CCC

69384

Cold agglutinins

CAG

65114

Collagen — low bone

CBLB

66773

Collagen — metabolic disease

CBMB

66776

Compatability testing

XMAT

65099-108

Complement, total haemolytic

COM

71081

Complement, total haemolytic — components C3

C3

71083

Complement, total haemolytic — components C4

C4

71083

Complement, total haemolytic — other components

COMP

71089

Complement, total haemolytic — properdin factor B

PFB

71083

Copper

CU

66668

Cortisol

CORT

66695

Coxsackie B1-6 — microbial antibody testing 

COX

69384

C-Peptide

CPEP

66695

C-reactive protein

CRP

66500

Creatine kinase

CK

66500

Creatine kinase — isoenzymes

CKI

66518

Creatine kinase — isoenzymes (electrophoresis)

CKIE

66518

Creatinine

C

66500

Cryofibrinogen — qualitative

CFID

71064

Cryofibrinogen — quantitative

CFIE

71064

Cryoglobulins — investigation by immunoelectrophoresis or  immunofixation 

RYO

71059

Cryoglobulins — qualitative

CGLD

71064

Cryoglobulins — quantitative

CGLE

71064

Cryptococcal antigen — microbial antigen testing

CRYN

69372

Cryptococus — microbial antibody testing

CRY

69384

CSF — microscopy & culture of material from

MCS3

69321

CSF antigens — group B streptococcus

STB

69372

CSF antigens — Haemophilus influenzae

HI

69372

CSF antigens — Neisseria meningitidis

NMG

69372

CSF antigens — Streptoccus pneumoniae

SPN

69372

Cultural examination of faeces

FCS

69345-51

Cyclic AMP

CAMP

66695

Cyclosporin A

CLSA

66611

Cystine — qualitative

UCYS

66752

Cystine — quantitative

CYST

66752

Cytology — fine needle aspiration of solid tissues

FNCY

73049

Cytology — fine needle aspiration of solid tissues — aspiration or attendance by a pathologist 

FNCP

73051

Cytology — from 3 sputum or urine specimens

SPCY

73047

Cytology — from body fluids, sputum (1 specimen), urine, washings or brushings

BFCY

73045

Cytology — from cervix — abnormalities

CCRA

73055

Cytology — from cervix — routine

CCR

73053

Cytology — from skin, nipple discharge, lip, mouth, nose or anus

SMCY

73043

Cytology — from vagina

CVO

73057

Cytomegalovirus — microbial antibody testing

CMV

69384

Cytomegalovirus serology in pregnancy — microbial antibody testing 

CMVP

69405-11

D vitamin

VITD

66608

D-dimer test

DD

65120

Dehydroepiandrosterone sulphate (DHEAS)

DHEA

66695

Dengue — microbial antibody testing

DEN

69384

11 — Deoxycortisol

DCOR

66695

Desipramine

DESI

66611

Determination HepB/HepC

HBC

69462

Dexamethasone

DXST

66686

Dexamethasone — suppression test

DEXA

66686

DHEAS (Dehydroepiandrosterone sulphate)

DHEA

66695

Diazepam

DIAZ

66611

Differential cell count

DIFF

65063

Digoxin

DIG

66611

Dihydrotestosterone

DHTS

66695

Diphenylhydantoin (Dilantin)

DIL

66611

Diphtheria — microbial antibody testing

DIP

69384

Direct Coombs test

CMBS

65114

Disopyramide (Rythmodan)

DISO

66611

DNA binding — quantitation & measurement if positive ANA

ANAP

71099

DNA, double-stranded antibodies

DNAD

71099

Donath Landsteiner antibody test

DLAT       

65075

Down’s syndrome and neural tube defects

NTDD

66740

Doxepin hydrochloride

DOXE

66611

Drugs — abuse treatment programme — assay

DATP

66626

Drugs — inappropriate dosage — assay

DRGO

66623

Drugs — therapeutic — assay (see individual drugs)

 

66611

Drugs not listed must be written in full

 

 

Dynamic function tests

GHSE

66686

Ear — microscopy & culture of material from

MCS1

69303

Echinococcus — microbial antibody testing

ECC

69384

Echis test

ECHI

65120

Echo-coxsackie group — microbial antibody testing

ECH

69384

Electrolytes (see group tests in Division A)

E

66509

Electron microscopy of biopsy material

EM

72851-52

Electrophoresis, to demonstrate — creatine kinase isoenzymes

CKIE

66518

Electrophoresis, to demonstrate — lactate dehydrogenase isoenzymes

LDI

66641

Electrophoresis, to demonstrate — lipoprotein subclasses

LEPG

66539

Electrophoresis, to demonstrate — protein classes, or paraprotein

EPP1

71057

Elements (see individual elements)

 

 

Entamoeba histolytica — microbial antibody testing

AMO

69384

Enzyme assays of solid tissue or tissues

ENZS

66683

Enzyme histochemistry of skeletal muscle

EHSK

72844

Eosinophil cationic protein

ECP

71095

Epstein Barr virus — microbial antibody testing

EBV

69384

Erythrocyte — assessment of haemolysis

ERYH

65075

Erythrocyte — assessment of metabolic enzymes

ERYM

65075

Erythrocyte — count

RCC

65063

Erythrocyte — sedimentation rate

ESR

65060

Ethosuximide (Zarontin)

ETHO

66611

Euglobulin clot lysis time

ECLT

65132

Extractable nuclear antigens — detection of antibodies to

ENA

71101

Eye — microscopy & culture of material from

MCS1

69303

Factor II

FII

65150

Factor IX

FIX

65150

Factor V

FV

65150

Factor VII 

FVII

65150

Factor VIII

VIII

65150

Factor X

FX

65150

Factor XI

FXI

65150

Factor XII

FXII

65150

Factor XIII

XIII

65150

Factor XIII deficiency test

F13D

65120

Faecal antigen test for Helicobacter pylori

FAHP

69366

Faecal blood

FOB

66764-70

Faecal fat

FFAT

66674

Faecal fat — haemoglobin

FFH

66764

Faecal fat — reducing substances

FRS

66761

Faeces —  culture

FCS

69345-51

Faeces — microscopy for parasites

OCP

69336-42

Ferritin (see also Iron studies)

FERR

66593

Fibrin monomer

FM

65120

Fibrinogen

FIB

65120

Fibrinogen — degradation products

FDP

65120

Fitzgerald factor

FGF

65150

Flecainide

FLEC

66611

Fletcher factor

FF

65150

Fluorescent treponemal antibody  — absorption test (FTA-ABS) — microbial antibody testing

FTA

69384

Fluoxetine

FLUX

66611

Foetal red blood cells — Kliehauer

KLEI

65162

Folate — red cell

RCF

66602

Follicle stimulating hormone (FSH)

FSH

66695

Frozen section diagnosis of biopsy material

FS

72855-56

Fructosamine

FRUC

66557

Full blood examination

FBE

65069

Gamma glutamyl transpeptidase

GGT

66500

Gastric parietal cell — tissue antigens — antibodies

PCA

71119

Gastrin

GAST

66695

Gliadin IgA — tissue antigens — antibodies

GLIA

71119

Globulin

GLOB

66500

Glomerular basement membrane — tissue antigens — antibodies

GBA

71109

Glucagon

GLGO

66695

Glucagon stimulation test

GSTC

66689

Glucose

GLUC

66500

Glucose — tolerance test

GTT

66542

Glycolated haemoglobin (Hb Alc)

GHB

66551

Glycosylated haemoglobin (Hb Alc)

GHB

66551

Gold

AU

66668

Gonadotrophin

GRHS

66689

Group B streptococcus — CSF antigens

STB

69372

Group B streptococcus — microbial antigen testing

STB

69372

Group P9 — simple basic pathology tests

 

73801-11

Growth hormone

GH

66695

Growth hormone — stimulation by exercise or L-dopa

GHSE

66686

Growth hormone — suppression by dexamethasone or glucose

GHSG

66686

Haematocrit

HCT

65063

Haemochromatosis

FEUP

66794

Haemoglobin

HB

65060

Haemoglobinopathy tests

HMGP

65081

Haemophilus influenzae — CSF antigens

HI

69372

Haemophilus influenzae — microbial antibody testing

HUS

69384

Haemophilus influenzae — microbial antigen testing

HI

69372

Haloperidol

HALO

66611

Haptoglobins

HGLB

66632

HDL cholesterol

HDLC

66536

Heart — tissue antigens — antibodies

AHE

71109

Heparin — cofactor II

HRNC

65132

Heparin — test

HEPR

65144

Hepatitis — acute

HAVM

69414

Hepatitis — chronic viral

HBCS

69453

Hepatitis — chronic viral

HBCE

69456

Hepatitis A — immune status

HAVG

69417

Hepatitis A and B — immune status

HABI

69450

Hepatitis A, B or C — acute

HVU

69459

Hepatitis B — acute or resolving

HBAR

69420

Hepatitis B — chronic or carriage of Hepatitis B antigen

HBSA

69432

Hepatitis B — chronic or carriage of Hepatitis B antigen

HBSE

69435

Hepatitis B — immune status — post exposure

HBIC

69426

Hepatitis B — immune status — post vaccination

HBIS

69429

Hepatitis B — resolving

HBR

69423

Hepatitis B and A — immune status

HABI

69450

Hepatitis C — detection

RNAC

69444

Hepatitis C — Hep. C antibody test

HCV

69438

Hepatitis D — acute or chronic

HDV

69447

Hepatitis serology — in pregnancy

HEPP

69405-11

Herpes simplex virus — direct detection from clinical material

HSV

69375

Herpes simplex virus — investigation by culture

HSVC

69375

Herpes simplex virus — microbial antibody testing

HPA

69384

Herpes simplex virus — microbial antigen testing

HSV

69375

Heterophil antibodies

IM

65114

HIAA (hydroxyindoleacetic acid)

HIAA

66779

Histamine

HIAM

66779

Histone — tissue antigens — antibodies

AHI

71109

Histopathology of biopsy material

HIST

72813-36

Histoplasma — microbial antibody testing

HIP

69384

HIV — antiretroviral therapy

TVLT

69381

HIV — monitoring

MVLT

69378

HLA typing — HLA class 1

HLA1

71149

HLA typing — HLA class 2

HLA2

71151

HLA typing — HLA-B27

HLAB

71147

HMMA (hydroxy-3-methoxymandelic acid, previously known as VMA) 

HMMA

66779

HMPG (hydroxy-methoxy phenylethylene glycol)

HMPG

66779

Homovanillic acid

HVA

66779

Hormomes — stimulation by exercise or L‑dopa

GHSE

66686

Hormone receptor assay — breast

HRA

66662

Hormone receptor assay — ovary

HRO

66662

Hormones — 11 deoxycortisol

DCOR

66695

Hormones — adrenocorticotrophic hormone

ACTH

66695

Hormones — aldosterone

ALDS

66695

Hormones — androstenedione

ANDR

66695

Hormones — calcitonin

CALT

66695

Hormones — cortisol

CORT

66695

Hormones — C-Peptide

CPEP

66695

Hormones — cyclic AMP

CAMP

66695

Hormones — dehydroepiandrosterone sulphate (DHEAS)

DHEA

66695

Hormones — dihydrotestosterone

DHTS

66695

Hormones — follicle stimulating hormone

FSH

66695

Hormones — gastrin

GAST

66695

Hormones — glucagon

GLGO

66695

Hormones — gonadotrophin

GRHS

66689

Hormones — growth hormone

GH

66695

Hormones — growth hormone — stimulation by exercise or L-dopa

GHSE

66686

Hormones — growth hormone — suppression by dexamethasone or glucose

GHSG

66686

Hormones — hormone receptor assay — breast

HRA

66662

Hormones — hormone receptor assay — ovary

HRO

66662

Hormones — human chorionic gonadotrophin — for diagnosis of specified conditions

HCGD

73529

Hormones — human chorionic gonadotrophin — for pregnancy diagnosis

HCG

73527

Hormones — human placental lactogen 

HPL

66746

Hormones — hydroxyprogesterone

OHP

66695

Hormones — insulin

INS

66695

Hormones — insulin, hypoglycaemia test

INHY

66689

Hormones — luteinizing hormone

LH

66695

Hormones — oestradiol

E2 

66695

Hormones — oestriol

E3

66746

Hormones — oestrone

E1

66695

Hormones — parathyroid hormone

PTH

66695

Hormones — pentagastrin

PSTR

66689

Hormones — progesterone

PROG

66695

Hormones — prolactin

PROL

66695

Hormones — renin

REN

66695

Hormones — sex hormone binding globulin

SHBG

66695

Hormones — somatomedin

SOMA

66695

Hormones — suppression by dexamethasone or glucose

GHSG

66686

Hormones — testosterone

TES

66695

Hormones — urine steroid fraction or fractions

USF

66695

Hormones — vasoactive intestinal peptide

VIP

66695

Hormones — vasopressin

ADH

66695

Hormones & hormone binding proteins (see individual hormones and proteins)

 

66695

Huhner’s test

HT

73521

Human chorionic gonadotrophin — for diagnosis of specified conditions

HCGD

73529

Human chorionic gonadotrophin — for Down’s syndrome and neural tube defect testing

NTDD

66740

Human chorionic gonadotrophin — for pregnancy diagnosis

HCG

73527

Human placental lactogen

HPL

66746

HVA (homovanillic acid)

HVA

66779

Hydatid — microbial antibody testing

HYD

69384

Hydroxy methoxy phenylethylene glycol

HMPG

66779

Hydroxy-3-methoxymandelic acid, previously known as VMA) 

HMMA

66779

Hydroxychloroquine 

HOCQ

66611

Hydroxyindoleacetic acid

HIAA

66779

Hydroxyprogesterone

OHP

66695

Hydroxyproline

HYDP

66752

Imipramine

IMIP

66611

Immediate frozen section diagnosis of biopsy material

FS

72855-856

Immunocyto. 1-3 antibodies

ICC

73059

Immunocyto. 4+ antibodies

ICC1

73060

Immunoglobulins — A 

IGA

71067

Immunoglobulins — D 

IGD 

71067

Immunoglobulins — E (total) 

IGE

71075-79

Immunoglobulins — G  

IGG

71067

Immunoglobulins — G, 4 subclasses

SIGG

71073

Immunoglobulins — M  

IGM

71067

Immunohistochemical investigation of biopsy material 

HIS

72846-47

Infectious mononucleosis

IM

69384

Influenza A — microbial antibody testing 

FLA

69384

Influenza B — microbial antibody testing 

FLB

69384

Insulin

INS

66695

Insulin — hypoglycaemia test 

INHY

66689

Insulin — tissue antigens — antibodies

AINS

71109

Insulin receptor antibodies — tissue antigens — antibodies

INSA

71109

Intercellular cement substance of skin — tissue antigens — antibodies

ICCS

71109

Intestinal disaccharidases

INTD

66680

Intrinsic factor — tissue antigens — antibodies

AIF

71109

Invest. HepA/HepC

HAC

69468

Iron studies (iron, transferrin & ferritin)

IS

66596

Islet cell — tissue antigens — antibodies

AIC

71109

Jo-1 — tissue antigens — antibodies

JO1

71119

Keratin — tissue antigens — antibodies

KERA

71119

Kleihauer test

KLEI

65162

Lactate

LACT

66500

Lactate — dehydrogenase

LDH

66500

Lactate — dehydrogenase isoenzymes

LDI

66641

Lamellar body phospholipid

LBPH

66749

Lead

PB

66665

Lecithin/sphingomyelin ratio (amniotic fluid) 

LS

66749

Legionella pneumophila — serogroup 1 — microbial antibody testing  

LP1

69384

Legionella pneumophila — serogroup 2 — microbial antibody testing

LP2

69384

Leishmaniasis — microbial antibody testing 

LEI

69384

Leptospira — microbial antibody testing  

LEP

69384

Leucocyte count

WCC

65063

Leucocyte count — 3 surface markers — blood, CSF, serous fluid

LMH3 

71139

Leucocyte count — 3 surface markers — tissue

LMT3 

71141

Leucocyte count — 6 surface markers — blood, CSF, serous fluid & tissue (s)

LMHT

71145

Leucocyte count — 6 surface markers — blood, CSF, serous fluid or tissue

LM6 

71143

Lignocaine

LIGN

66611

Lip — cytology on specimens from

SMCY

73043

Lipase

LIP

66500

Lipid studies (see group tests in Division A)

FATS

66521

Lipoprotein subclasses — electrophoresis 

LEPG

66539

Listeria — microbial antibody testing

LIS

69384

Lithium

LI

66611

Liver function tests (see group tests in Division A)

LFT

66515

Liver/kidney microsomes — tissue antigens — antibodies

LKA

71119

Lupus anticoagulant

LUPA

65132

Luteinizing hormone

LH

66695

Lymphocyte — tissue antigens — antibodies

ALY

71109

Lymphocytes — functional tests — 1 test

LF1

71127

Lymphocytes — functional tests — 2 tests

LF2

71129

Lymphocytes — functional tests — 3 tests

LF3 

71131

Magnesium

MG

66500

Mammary serum antigen 

MSA

66650

Manganese

MN

66668

Mantoux test

MANT

73811

Measles — microbial antibody testing

MEA

69384

Mercury

HG

66668

Metabolic bone disease

CBMB

66776

Metalbumin detection (Schumm’s test)

SCHM

65117

Metanephrines

MNEP

66779

Methadone

MTDN

66611

Methotrexate

MTTA

66611

Methsuximide 

MSUX

66611

Metronidazole

MRDZ

66611

Mexiletine (Mexitil)

MEX

66611

Mianserin

MIAS

66611

Microalbumin

MALB

66560

Microbial antibody testing — actinomycetes

ACT

69384

Microbial antibody testing — adenovirus

ADE

69384

Microbial antibody testing — aspergillus

ASP

69384

Microbial antibody testing — avian precipitins (bird fancier’s disease)

APP

69384

Microbial antibody testing — Blastomyces

BLM

69384

Microbial antibody testing — Bordetella pertussis

BOR

69384

Microbial antibody testing — Borrelia burgdorferi

BOB

69384

Microbial antibody testing — Brucella

BRU

69384

Microbial antibody testing — Campylobacter jejuni

CAM

69384

Microbial antibody testing — Candida

CAN

69384

Microbial antibody testing — Chlamydia

CHL

69384

Microbial antibody testing — Coccidioides 

CCC

69384

Microbial antibody testing — Coxsackie B1‑6

COX

69384

Microbial antibody testing — cryptococus

CRY

69384

Microbial antibody testing — cytomegalovirus

CMV

69384

Microbial antibody testing — cytomegalovirus serology in pregnancy

CMVP

69384

Microbial antibody testing — dengue

DEN

69384

Microbial antibody testing — diphtheria

DIP

69384

Microbial antibody testing — echinococcus

ECC

69384

Microbial antibody testing — echo-coxsackie group

ECH

69384

Microbial antibody testing — Entamoeba histolytica

AMO

69384

Microbial antibody testing — Epstein Barr virus

EBV

69384

Microbial antibody testing — fluorescent treponemal antibody  — absorption test (FTA-ABS)

FTA

69384

Microbial antibody testing — Haemophilus influenzae

HUS

69384

Microbial antibody testing — hepatitis C

HCV

69438

Microbial antibody testing — herpes simplex virus

HPA

69384

Microbial antibody testing — Histoplasma

HIP

69384

Microbial antibody testing — hydatid

HYD

69384

Microbial antibody testing — infectious mononucleosis  

IM

69384

Microbial antibody testing — influenza A

FLA

69384

Microbial antibody testing — influenza B

FLB

69384

Microbial antibody testing — Legionella pneumophila — serogroup 1

LP1

69384

Microbial antibody testing — Legionella pneumophila — serogroup 2

LP2

69384

Microbial antibody testing — leishmaniasis

LEI

69384

Microbial antibody testing — Leptospira

LEP

69384

Microbial antibody testing — Listeria

LIS

69384

Microbial antibody testing — measles

MEA

69384

Microbial antibody testing — Micropolyspora faeni

MIC

69384

Microbial antibody testing — mumps

MUM

69384

Microbial antibody testing — Murray Valley encephalitis

MVE

69384

Microbial antibody testing — Mycoplasma pneumoniae

MYC

69384

Microbial antibody testing — Neisseria menigitidis

MEN

69384

Microbial antibody testing — Newcastle disease

NCD

69384

Microbial antibody testing — parainfluenza 1

PF1

69384

Microbial antibody testing — parainfluenza 2

PF2

69384

Microbial antibody testing — parainfluenza 3

PF3

69384

Microbial antibody testing — paratyphi

PTY

69384

Microbial antibody testing — pertussis

PER

69384

Microbial antibody testing — poliomyelitis

PLO

69384

Microbial antibody testing — Proteus OX 19

POX

69384

Microbial antibody testing — Proteus OXK

POK

69384

Microbial antibody testing — Q fever

QFF

69384

Microbial antibody testing — rapid plasma reagin test

RPR

69384

Microbial antibody testing — respiratory syncytial virus

RSV

69384

Microbial antibody testing — Ross River virus

RRV

69384

Microbial antibody testing — rubella

RUB

69384

Microbial antibody testing — Salmonella typhi (H)

SAH

69384

Microbial antibody testing — Salmonella typhi (O)

SAO

69384

Microbial antibody testing — Schistosoma

STO

69384

Microbial antibody testing — streptococcal serology — anti-DNASE B titre

ADNB

69384

Microbial antibody testing — streptococcal serology — anti-streptolysin O titre

ASOT

69384

Microbial antibody testing — Streptococcus pneumoniae 

PCC

69384

Microbial antibody testing — tetanus

TET

69384

Microbial antibody testing — Thermoactinomyces vulgaris

THE

69384

Microbial antibody testing — thermopolyspora

TPS

69384

Microbial antibody testing — Toxocara

TOC

69384

Microbial antibody testing — toxoplasma

TOX

69384

Microbial antibody testing — TPHA (Treponema pallidum haemagglutination test)

TPHA

69384

Microbial antibody testing — Treponema pallidum haemagglutination test

TPHA

69384

Microbial antibody testing — trichinosis

TOS

69384

Microbial antibody testing — typhus, Weil‑Felix

TYP

69384

Microbial antibody testing — Varicella zoster

VCZ

69384

Microbial antibody testing — VDRL (Venereal Disease Research Laboratory)

VDRL

69384

Microbial antibody testing — Yersinia enterocolitica

YER

69384

Microbial antigen testing — Chlamydia

CHLY

69315, 69369

Microbial antigen testing — Clostridium difficile

CLDT

69363

Microbial antigen testing — group B streptococcus

STB

69372

Microbial antigen testing — Haemophilus influenzae

HI

69372

Microbial antigen testing — herpes simplex virus

HSV

69375

Microbial antigen testing — Neisseria gonorrhoeae

GON

69372

Microbial antigen testing — Neisseria meningitidis

NMG

69372

Microbial antigen testing — respiratory syncytial virus

RSVN

69372

Microbial antigen testing — Streptococcus pneumoniae

SPN

69372

Microbial antigen testing — Varicella zoster

VCZN

69375

Micropolyspora faeni 

MIC

69384

Microscopic examination of — faeces for parasites

OCP

69336-42

Microscopic examination of — material other than blood

M

69300

Microscopy & culture of — material from nose, throat, eye or ear

MCS1 

69303

Microscopy & culture of — material from skin, superficial sites, urethra, vagina, cervix or rectum    

MCS2

69306-15

Microscopy & culture of — specimens of sputum

MCS2

69318

Microscopy & culture of — specimens of sputum, urine or other body fluids for mycobacteria

AFB

69324-30

Microscopy & culture to detect pathogenic micro‑organisms including chlamydia

MCS4

69315

Microscopy, culture, identification & sensitivity of urine

UMCS

69333

Mitochondria — tissue antigens — antibodies

MA

71119

Mouth — cytology on specimens from

SMCY

73043

Mumps — microbial antibody testing

MUM

69384

Murray Valley encephalitis — microbial antibody testing

MVE

69384

Mycobacteria microscopy & culture of sputum

AFB

69324-330

Mycoplasma pneumoniae — microbial antibody testing 

MYC

69384

Myoglobin

MYOG

66518

N-acetyl procainamide

NAPC

66611

Neisseria gonorrhoeae — microbial antigen testing

GON

69372

Neisseria menigitidis — antigens

NMG

69372

Neisseria menigitidis — microbial antibody testing 

MEN

69384

Neisseria menigitidis — microbial antigen testing

NMG

69372

Neural tube defects and Down’s syndrome

NTDD

66740

Neuron — tissue antigens — antibodies

ANE

71109

Neutrophil cytoplasm — tissue antigens — antibodies

ANCA

71109

Neutrophil functions

NFT

71135

Newcastle disease — microbial antibody testing 

NCD

69384

Nickel

NI

66668

Nipple discharge — cytology on specimens from

SMCY

73043

Nitrazepam

NITR

66611

Nordothiepin

NDIP

66611

Norfluoxetine

NFLE

66611

Nortriptyline

NORT

66611

Nose — cytology on specimens from

SMCY

73043

Nose — microscopy & culture of material from

MCS1

69303

Nuclear antigens — detection of antibodies to

ANA

71097

Oestradiol

E2

66695

Oestriol

E3

66746

Oestriol — for Down’s syndrome and neural tube defect testing

NTDD

66740

Oestrone

E1

66695

Oligoclonal proteins

OGP

71062

Op/biopsy specimens — microscopy & culture of material from

MCS3

69321

Oral glucose challenge test — gestational diabetes

OGCT

66545

Oral glucose tolerance test — gestational diabetes

GTTP

66542

Osmolality, serum or urine

OSML

66563

Ovary — tissue antigens — antibodies

AOV

71109

Oxalate

OXAL

66752

Oxazepam

OXAZ

66611

PAA (phenyl acetic acid)

PAA

66779

Palmitic acid in amniotic fluid

PALM

66749

Pap smear

CCR

73053

Papanicolaou test

CCR

73053

Paracetamol

PARA

66611

Parainfluenza 1 — microbial antibody testing

PF1

69384

Parainfluenza 2 — microbial antibody testing

PF2

69384

Parainfluenza 3 — microbial antibody testing

PF3

69384

Paraprotein investigation  — by immunoelectrophoresis or immunofixation 

PPRO

71059

Paraprotein investigation — by electrophoresis

EPPI

71057

Paraprotein investigation — on concurrently collected serum or urine 

PPSU

71060

Paraquat

PARQ

66611

Parasites — microscopic examination of faeces

OCP

69336-42

Parathyroid — tissue antigens — antibodies

PTHA

71109

Parathyroid hormone (PTH)